Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis in Transgender Women: A Secondary Analysis of the HPTN 083 Trial

Authors: Mark A Marzinke, Brett Hanscom, Zhe Wang, Steven A Safren, Christina Psaros, Deborah Donnell, Paul A Richardson, Philip Sullivan, HPTN 083 study group, and co.

Abstract

Background: The HIV Prevention Trials Network (HPTN) 083 trial showed that long-acting injectable cabotegravir was more effective than tenofovir disoproxil fumarate plus emtricitabine in preventing HIV in cisgender men and transgender women who have sex with men. We aimed to characterize the cohort of transgender women included in HPTN 083.

Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis in Transgender Women: A Secondary Analysis of the HPTN 083 Trial

Abstract

Available Resources

Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis in Transgender Women: A Secondary Analysis of the HPTN 083 Trial

Enter keyword:

Select a category:

Select a tag:

Select a location:

Related Items

Differentiated Care for Adults at High Risk of HIV Disease Progression: A Call to Action

HIV-Related Stigma, Social Support, and Psychological Distress Among Individuals Initiating ART in Ethiopia.

Youth-friendly services and differentiated models of care are needed to improve outcomes for young people living with HIV.

Building on the HIV chronic care platform to address noncommunicable diseases in sub-Saharan Africa: a research agenda

Subscribe To Our Newsletter

Please check your email to confirm your subscription.

Subscribe To Our Newsletter

Please check your email to confirm your subscription.